Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Viela Bio.

    Client Virtual Booth

    VIELA BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Viela Bio
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One MedImmune Way First Floor, Area Two Gaithersburg, MD 20878
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vielabio.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/viela-bio
    Twitter
    Twitter
    https://twitter.com/vielabio?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Inflammatory Disease Biotech Ventyx Biosciences Files for A $100 Million IPO

    Details:

    VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor that it believes has the potential to address a broad range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus.


    Lead Product(s): VTX958

    Therapeutic Area: Immunology Product Name: VTX958

    Highest Development Status: Phase IProduct Type: Small molecule

    Recipient: Ventyx Biosciences

    Deal Size: $100.0 million Upfront Cash: Undisclosed

    Deal Type: Public Offering September 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.

    Details:

    Horizon Therapeutics gets UPLIZNA, first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder.


    Lead Product(s): Inebilizumab

    Therapeutic Area: Immunology Product Name: Uplizna

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Horizon Therapeutics

    Deal Size: $3,005.0 million Upfront Cash: $3,005.0 million

    Deal Type: Acquisition March 15, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Horizon Therapeutics to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

    Details:

    Horizon adds UPLIZNA® (inebilizumab-cdon) to its commercial rare disease medicine portfolio. The acquisition Adds deep, mid-stage biologics pipeline focused primarily on autoimmune and severe inflammatory diseases.


    Lead Product(s): Inebilizumab

    Therapeutic Area: Immunology Product Name: Uplizna

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Horizon Therapeutics

    Deal Size: $3,005.0 million Upfront Cash: $3,005.0 million

    Deal Type: Acquisition February 01, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020

    Details:

    First poster will highlights study results in AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.


    Lead Product(s): Inebilizumab

    Therapeutic Area: Immunology Product Name: Uplizna

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 03, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

    Details:

    The interim findings indicated safety and tolerability comparable to placebo control across all cohorts, potent depletion of pDC both in peripheral blood and in inflamed CLE skin lesion biopsies in cohort 2, and dose-dependent reduction in CLASI after treatment with VIB7734.


    Lead Product(s): VIB7734

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search